Cargando…
Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey
OBJECTIVES: To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. METHOD: Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469236/ https://www.ncbi.nlm.nih.gov/pubmed/37646470 http://dx.doi.org/10.1177/10732748231182795 |
_version_ | 1785099398473056256 |
---|---|
author | Richardson, Michael T. Attwood, Kristopher Smith, Gabriella Liang, Su-Ying LaVigne Mager, Katherine Tewari, Krishnansu S. Coleman, Robert L. Kapp, Daniel S. Chan, John K. Monk, Bradley J. |
author_facet | Richardson, Michael T. Attwood, Kristopher Smith, Gabriella Liang, Su-Ying LaVigne Mager, Katherine Tewari, Krishnansu S. Coleman, Robert L. Kapp, Daniel S. Chan, John K. Monk, Bradley J. |
author_sort | Richardson, Michael T. |
collection | PubMed |
description | OBJECTIVES: To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. METHOD: Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-826, and tisotumab vedotin (tiso) from GOG 3023. Costs were based on IBM Micromedex RED BOOK™ and company listed costs. RESULTS: For [chemo + bev → chemo], total cost was $125,918.04, with median overall survival (mOS) of 21.8 months, and cost-effectiveness ratio (CER) of $119,835.79. For [chemo + bev → cemi], total cost was $187,562.99 with mOS of 28.5 months and CER of $162,039.16. For [chemo + bev + pembro → chemo], total cost was $319,963.78 with mOS 32.9 months and CER of $249,930.10. For [chemo + bev + pembro → tiso], total cost was $455,204.45, with mOS 36.5 months and CER of $320,072.99. CONCLUSION: The combination of immunotherapies and biologics have significantly increased overall survival, but with associated higher costs, primarily related to drug costs. |
format | Online Article Text |
id | pubmed-10469236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-104692362023-09-01 Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey Richardson, Michael T. Attwood, Kristopher Smith, Gabriella Liang, Su-Ying LaVigne Mager, Katherine Tewari, Krishnansu S. Coleman, Robert L. Kapp, Daniel S. Chan, John K. Monk, Bradley J. Cancer Control Original Research Article OBJECTIVES: To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. METHOD: Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-826, and tisotumab vedotin (tiso) from GOG 3023. Costs were based on IBM Micromedex RED BOOK™ and company listed costs. RESULTS: For [chemo + bev → chemo], total cost was $125,918.04, with median overall survival (mOS) of 21.8 months, and cost-effectiveness ratio (CER) of $119,835.79. For [chemo + bev → cemi], total cost was $187,562.99 with mOS of 28.5 months and CER of $162,039.16. For [chemo + bev + pembro → chemo], total cost was $319,963.78 with mOS 32.9 months and CER of $249,930.10. For [chemo + bev + pembro → tiso], total cost was $455,204.45, with mOS 36.5 months and CER of $320,072.99. CONCLUSION: The combination of immunotherapies and biologics have significantly increased overall survival, but with associated higher costs, primarily related to drug costs. SAGE Publications 2023-08-30 /pmc/articles/PMC10469236/ /pubmed/37646470 http://dx.doi.org/10.1177/10732748231182795 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Richardson, Michael T. Attwood, Kristopher Smith, Gabriella Liang, Su-Ying LaVigne Mager, Katherine Tewari, Krishnansu S. Coleman, Robert L. Kapp, Daniel S. Chan, John K. Monk, Bradley J. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey |
title | Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey |
title_full | Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey |
title_fullStr | Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey |
title_full_unstemmed | Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey |
title_short | Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey |
title_sort | sequential targeted therapy for advanced, metastatic, and recurrent cervical cancer: a cost-effectiveness analysis of the patient journey |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469236/ https://www.ncbi.nlm.nih.gov/pubmed/37646470 http://dx.doi.org/10.1177/10732748231182795 |
work_keys_str_mv | AT richardsonmichaelt sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT attwoodkristopher sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT smithgabriella sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT liangsuying sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT lavignemagerkatherine sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT tewarikrishnansus sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT colemanrobertl sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT kappdaniels sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT chanjohnk sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney AT monkbradleyj sequentialtargetedtherapyforadvancedmetastaticandrecurrentcervicalcanceracosteffectivenessanalysisofthepatientjourney |